Bank Of New York Mellon Corp Ikena Oncology, Inc. Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.23 - $7.4 $247,040 - $565,974	-76,483 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$5.61 - $13.85 $7,736 - $19,099	-1,379 Reduced 1.77%	76,483 $466,000
Q4 2021 Feb 11, 2022	BUY	$10.52 - $16.96 $578,473 - $932,596	54,988 Added 240.4%	77,862 $977,000
Q3 2021 Nov 12, 2021	BUY	$9.82 - $15.23 $47,145 - $73,119	4,801 Added 26.56%	22,874 $288,000
Q2 2021 Aug 11, 2021	BUY	$13.27 - $26.0 $239,828 - $469,898	18,073 New	18,073 $253,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $61.3M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.